Status | Study |
Enrolling by invitation |
Study Name: Persistence of the Immune Response After Ebola Vaccine Immunisation Condition: Ebola Virus Disease Date: 2017-05-02 |
Recruiting |
Study Name: PREVAIL VI: Identification of Host Genetic Factors Underlying Ebola Virus Disease Risk, Mortality, Long-term Sequelae, Viral RNA Persistence, Humoral Immunity, and Ebola Vaccine Response Condition: Ebola Virus Disease Date: 2017-03-30 |
Not yet recruiting |
Study Name: African-Canadian Study of HIV-Infected Adults and a Vaccine for Ebola - ACHIV-Ebola Condition: Ebola Date: 2016-12-22 Interventions: Biological: V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine |
Recruiting |
Study Name: Open Study of the Duration of Immunity After Vaccination With GamEvac Condition: Hemorrhagic Fever, Ebola Date: 2016-09-14 Interventions: Procedure: blood sampling collection It is an observational study; no interventions are planned in the c |
Recruiting |
Study Name: Partnership for Research on Ebola VACcinations Condition: Ebola Virus Disease Date: 2016-08-16 Interventions: Biological: Ad26.ZEBOV 0.5 mL |
Recruiting |
Study Name: GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in Semen Condition: Persistent Ebola Virus Date: 2016-06-28 Interventions: Drug: GS-5734 Daily GS-5734 de |
Completed |
Study Name: Trial to Evaluate Safety and Immunogenicity of an Ebola Zaire Vaccine in Healthy Adults Condition: Ebola Virus Disease Date: 2016-03-09 Interventions: Biological: Ebola Vaccine - low dose |
Recruiting |
Study Name: Tolerance and Activity Evaluation of High Doses of Favipiravir Against Ebola Virus in the Semen Condition: Ebola Virus Survivor Date: 2016-02-24 Interventions: Drug: Favipiravir Cohort 1: Day 1 (inclusion) 4800 mg (240 |
Recruiting |
Study Name: Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo Condition: Hemorrhagic Fever, Ebola Date: 2016-01-08 Interventions: Biological: Ad26.ZEBOV No vacc |
Recruiting |
Study Name: Safety, Tolerability and Immunogenicity Study of 2 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo Condition: Hemorrhagic Fever, Ebola Date: 2015-11-04 Interventions: Biological: Ad26.ZEBOV One 0.5 |